

## Format for ANSWERING REVIEWERS



May 30, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 10008-review.doc).

**Title:** Recent advances of CD74 in cancer

**Author:** Yu-Huei Liu, Jung-Yaw Lin

**Name of Journal:** *World Journal of Immunology*

**ESPS Manuscript NO:** 10008-review

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewers:

**Comments from 02929417**

**(1) GENERAL COMMENTS** The article is a comprehensive overview of CD74 in various cancers and is well written.

**Ans.** We thank reviewer's comments.

**(2) SPECIFIC COMMENTS** The manuscript, according to me, can be accepted after certain revisions. My main concerns are

(2.1) The grammatical errors in section 1.1, precisely in the 2nd half of the paragraph, after the description of four major isoforms of CD74.

**Answer:** The grammatical errors have been revised.

(2.2) The legends in figure 2 can be made more descriptive to aid in proper understanding in mechanism of antigen presentation.

**Answer:** Additional description has been added in the legends in figure 2. [\[page 30 line 13-18\]](#)

(2.3) In section 2. (The physiological role of CD74 in the immune system), controversial statements have been made in relation to role of CD74 in immunity (Certain point's favor the role of CD74 in immunity while others are against the same). A proper justification seems to be lacking.

**Answer:** The statements have been made clearer about the role of CD74 in immunity. The justification has been made. [\[page 4 line 3-page 5 line 6\]](#)

(2.4) The role of CD74 in cancer has been well explained in the current review. My suggestion would be to include the therapeutic part mentioned in 2nd paragraph of section 3.2 (Oncogenic signaling through cell surface CD74) in Section 4 (i.e. 4. CD74-targeted cancer therapy)

**Answer:** The therapeutic part mentioned in 2nd paragraph of section 3.2 (Oncogenic signaling through cell surface CD74) has been included in Section 4 (i.e. 4. CD74-targeted cancer therapy) according to reviewer's comments.

[page 7 line 21-24]

(2.5) Section 4 which is based on CD74 targeted cancer therapy can be made more elaborative.

Answer: The examples about current finding about CD74 targeted cancer therapy have been added. [page 8 line 8-21]

**Comments from 00037961**

**(1) Comments To Authors**

This is a review on recent advances of CD 74 in cancer and is well presented.

CD74 participates in several immune responses such as antigen presentation and inflammation.

This evolutionarily conserved molecule plays a crucial role in some cancers.

CD74 promotes cell proliferation and motility and prevents cell death in a macrophage migration inhibitory factor (MIF)-dependent manner.

The role of CD 74 as an accessory cell surface receptor and their ability to interact with other signaling molecules make this cell cycle marker as an attractive therapeutic target for the treatment of cancer.

Several structural and functional variants of CD74 with their own expression pattern is known.

This review has taken into consideration some of these important advancements on the primary role of CD74 in the immune system and tumorigenesis.

Answer: We thank reviewer's comments.

**(2) Comments:**

Please provide the abstract in a manner as it was presented in the body of the text perhaps separating the differences about its role between immune system and cancer development.

The summary should reflect of the information presented and conclusions may be separated with prospective therapeutic targets in mind.

Answer: We have reorganized the abstract and summary according to reviewer's comment. [page 2 line 2-5; page 2 line 8-14; page 9 line 1; page 9 line 2-5]

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Immunology*.

Sincerely yours,



Jung-Yaw Lin, PhD, Professor

Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University.

Postal address: Room 942, No.1 Jen-Ai Road, Taipei 11051, Taiwan

Telephone: 886-2-23123456 ext 88206

Fax: 886-2-23954776

Email address: linjy@ntu.edu.tw